CO2021013524A2 - Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos - Google Patents

Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos

Info

Publication number
CO2021013524A2
CO2021013524A2 CONC2021/0013524A CO2021013524A CO2021013524A2 CO 2021013524 A2 CO2021013524 A2 CO 2021013524A2 CO 2021013524 A CO2021013524 A CO 2021013524A CO 2021013524 A2 CO2021013524 A2 CO 2021013524A2
Authority
CO
Colombia
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
CONC2021/0013524A
Other languages
English (en)
Inventor
Eric Voight
Zhaoming Xiong
Qingwei I Zhang
Christina Baumgartner
Jennifer M Frost
Christos Economou
Andrew Bogdan
Geoff T Halvorsen
Elliot P Farney
Philip R Kym
Mark A Matulenko
Matthew O'connor
Reza Shiroodi
Jason Abbott
Stacy Fosu
Original Assignee
Abbvie Inc
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Calico Life Sciences Llc filed Critical Abbvie Inc
Publication of CO2021013524A2 publication Critical patent/CO2021013524A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para la inhibición de la proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento de enfermedades, trastornos y afecciones relacionadas que responden favorablemente al tratamiento con un inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
CONC2021/0013524A 2019-03-14 2021-10-11 Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos CO2021013524A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2021013524A2 true CO2021013524A2 (es) 2022-02-28

Family

ID=70190226

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013524A CO2021013524A2 (es) 2019-03-14 2021-10-11 Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos

Country Status (22)

Country Link
US (1) US10851073B2 (es)
EP (1) EP3938038A1 (es)
JP (2) JP7204005B2 (es)
KR (2) KR20230074822A (es)
CN (2) CN116332873A (es)
AR (1) AR118374A1 (es)
AU (1) AU2020234712A1 (es)
BR (1) BR112021017430A2 (es)
CA (1) CA3131894A1 (es)
CL (1) CL2021002382A1 (es)
CO (1) CO2021013524A2 (es)
CR (1) CR20210516A (es)
DO (1) DOP2021000188A (es)
EC (1) ECSP21075909A (es)
IL (1) IL286373A (es)
MA (1) MA55301A (es)
MX (1) MX2021010544A (es)
PE (1) PE20212154A1 (es)
SG (1) SG11202109067PA (es)
TW (1) TW202100515A (es)
UY (1) UY38613A (es)
WO (1) WO2020186199A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116348455A (zh) * 2019-12-18 2023-06-27 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
CA3207923A1 (en) * 2021-02-12 2022-08-18 Seth P. Finklestein Compounds, compositions, and methods for modulating fgf activity
CN117279913A (zh) * 2021-03-11 2023-12-22 金橘生物科技公司 杂环化合物及其用途
EP4351558A1 (en) * 2021-06-10 2024-04-17 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
AU2022386164A1 (en) * 2021-11-11 2024-05-23 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023086498A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
TW202337459A (zh) * 2022-02-02 2023-10-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
TW202342437A (zh) * 2022-02-02 2023-11-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023179542A1 (en) * 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP1439834A1 (en) 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
WO2007115058A2 (en) 2006-03-31 2007-10-11 Novartis Ag Thiadiazolidinone inhibitors of ptpase
US20100160228A1 (en) 2007-05-23 2010-06-24 Valtion Teknillinen Tutkimuskeskus Method for inhibiting or stimulating angiogenesis in an individual
AR066820A1 (es) 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
US20130202577A1 (en) 2010-02-03 2013-08-08 Monash University Diagnostic and prognostic assay for breast cancer
US9828399B2 (en) 2014-02-28 2017-11-28 The Royal Institution For The Advancement Of Learning/Mcgill University TC-PTP inhibitors as APC activators for immunotherapy
WO2015188228A1 (en) 2014-06-10 2015-12-17 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)
CR20210017A (es) * 2018-06-21 2021-11-03 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatosa y sus métodos de uso

Also Published As

Publication number Publication date
JP7204005B2 (ja) 2023-01-13
JP2022522526A (ja) 2022-04-19
CL2021002382A1 (es) 2022-06-03
EP3938038A1 (en) 2022-01-19
PE20212154A1 (es) 2021-11-09
MX2021010544A (es) 2021-10-01
ECSP21075909A (es) 2021-11-30
UY38613A (es) 2020-09-30
BR112021017430A2 (pt) 2022-01-18
MA55301A (fr) 2022-01-19
US20200299246A1 (en) 2020-09-24
US10851073B2 (en) 2020-12-01
TW202100515A (zh) 2021-01-01
DOP2021000188A (es) 2022-03-15
IL286373A (en) 2021-10-31
AU2020234712A1 (en) 2021-09-09
KR20210151821A (ko) 2021-12-14
CN114025844A (zh) 2022-02-08
WO2020186199A1 (en) 2020-09-17
CN116332873A (zh) 2023-06-27
AR118374A1 (es) 2021-09-29
KR102533599B1 (ko) 2023-05-17
SG11202109067PA (en) 2021-09-29
JP2023052094A (ja) 2023-04-11
CR20210516A (es) 2022-07-19
KR20230074822A (ko) 2023-05-31
CA3131894A1 (en) 2020-09-17
CN114025844B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
ECSP21075909A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2020004534A (es) Moduladores de la vía integrada del estrés.
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
CL2020000382A1 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática.
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CL2021001488A1 (es) Transposasa de piggybac mutada
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
CO2022014499A2 (es) Moduladores de nlrp3
ECSP22001370A (es) Inhibidores de prmt5
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
CL2023002120A1 (es) Terapia combinada de un inhibidor de alk2 y un inhibidor de jak2
ECSP21042779A (es) Moduladores de la expresión de irf5
CO2023013780A2 (es) Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4
BR112022010672A2 (pt) Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica